Quick Answer
ARS Pharmaceuticals, Inc. reported Operating Income Loss of -$179.45 million for the year ending 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -5,720.6% in Operating Income Loss from 2024 to 2025.
- This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$5.24 million | Q2 2020: -$6.46 million | Q3 2020: -$8.11 million | Q1 2021: -$18.89 million | Q2 2021: -$24.51 million | Q3 2021: -$22.68 million | Q1 2022: -$7.10 million | Q2 2022: -$6.34 million | Q3 2022: -$6.63 million | Q1 2023: -$18.71 million | Q2 2023: -$20.60 million | Q3 2023: -$17.98 million | Q1 2024: -$13.19 million | Q2 2024: -$15.34 million | Q3 2024: -$21.75 million | Q1 2025: -$37.18 million | Q2 2025: -$47.61 million | Q3 2025: -$53.19 million.
- Over the full 6 years of available data (2020 to 2025), ARS Pharmaceuticals, Inc.'s Operating Income Loss has declined by 445.1%.
- Historical annual values: Fiscal year 2025: -$179.45 million | Fiscal year 2024: -$3.08 million | Fiscal year 2023: -$67.52 million | Fiscal year 2022: -$35.52 million | Fiscal year 2021: -$19.45 million | Fiscal year 2020: -$32.92 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: